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Stllilmsl'y 
Anticytokine therapies have been promulgated in gram-negative sepsis as a means of preventing 
or neutralizing excessive  production of  proinflammatory cytokines. However, systemic  administration 
of cytokine inhibitors is an inefficient means of targeting excessive  production in individual tissue 
compartments. In the present study, human gene transfer was used to deliver to organs of the 
reticuloendothelial system antagonists that either inhibit tumor necrosis factor-ol  (TNF-o  0 synthesis 
or block its interactions with cellular receptors. Mice were treated intraperitoneally with cationic 
liposomes containing 200 #g of either a pCMV (cytomegalovirus)/p55  expression plasmid that 
contains the extracellular domain and transmembrane region of the human p55 TNF receptor, 
or a pcD-SR-c~/hIL-10 expression plasmid containing the DNA for human interleukin 10. 48 h 
later, mice ycere challenged with lipopolysaccharide (LPS) and D-galactosamine. Pretreatment 
of mice with p55 or IL-10 cDNA-liposome complexes improved survival ~  <0.01) to LPS-D- 
galactosamine. In additional studies, intratracheal administration  of IL-10 DNA-liposome com- 
plexes 48 h before an intratracheal LPS challenge reduced pulmonary TNF-ol levels by 62% and 
decreased neutrophil infiltration  in the lung by 55% as measured by myeloperoxidase activity 
(both p <(0.05). Gene transfer with cytokine inhibitors is a promising option for the treatment 
of both the systemic and local sequelae of septic shock. 
I 
t is now recognized that many of the pathologic conse- 
quences of septic shock result from the overproduction 
of proinflammatory cytokines (1). Two independent lines of 
evidence support  the hypothesis that a single proinflamma- 
tory cytokine, TNF-oe, contributes to many of the patholog- 
ical changes  that occur in sepsis. First,  administration  of 
TNF-o~ to laboratory animals and patients reproduces the din- 
ical and pathological changes evident during overwhelming 
septic shock (2, 3). Second, neutralizing an exaggerated en- 
dogenous TNF  response with  soluble TNF  receptor  im- 
munoadhesins or down-regulating TNF-~ production with 
IL-10 pretreatment confers survival to otherwise lethal en- 
dotoxemia (4-6). Presently, clinical trials are under way with 
mAbs and immunoadhesins directed against TNF-o~ in pa- 
tients  with sepsis syndrome (7). 
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However, current therapeutic approaches are inherently 
inefficient. First,  these natural antagonists  or inhibitors  of 
TNF and IL-1 have  very short biological half-lives, ranging 
from minutes to hours (4, 8). In addition, TNF-ol levels are 
often several times higher in the inflamed tissue compart- 
ment than in the plasma (9, 10), and inhibitors must there- 
fore be given parenterally in large quantities to reach and sat- 
urate all tissue pools. Finally, exaggerated TNF-ol production 
may contribute to the pathology in one body compartment, 
while, simultaneously, production in another compartment 
may actually have beneficial effects. Thus, systemic adminis- 
tration of cytokine inhibitors at levels sufficient to neutralize 
exaggerated TNF production in one tissue compartment may 
also block the presumably  benefidal aspects of  cytokine produc- 
tion in other tissue compartments. 
To develop an alternative approach for anticytokine thera- 
pies, we investigated gene transfer of cytokine inhibitors  as 
a novel drug delivery system. Although gene transfer and 
transfection  studies are being actively pursued for patients 
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basis  of cancer,  diabetes,  and  other  chronic diseases,  gene 
transfer as a therapeutic modality for sepsis and acute inflam- 
mation is not as actively pursued.  However, the possibility 
of targeting  specific organs  to produce cytokine inhibitors 
or antagonists at local sites of inflammation makes transient 
gene transfer an attractive alternative to systemic adminis- 
tration. 
Materials and Methods 
Confirmation of Transgene Expression in Healthy Mice.  Healthy 
female C57BL/6j (15-17 g) mice were injected i.p.  with 200/~g 
of a pCMV expression plasmid that contains the open reading frame 
for the extracellular hinge regions of the human p55 DNA (11). 
The plasmid DNA (pCMV/p55) was mixed with 100 nmol of cat- 
ionic  liposomes  containing  equimolar  ratios  of  dimethyldioc- 
tadecylammonium bromide (DDAB): dioleoylphosphatidylethanol- 
amine (DOPE) (1 mM stock solution) in a total volume of 200/A 
(12, 13). This plasmid employs a human CMV immediate-early 
1 promoter-enhancer element that has been previously shown to 
be an effective expression vector in a variety of murine tissues (14). 
Additional animals were injected with 200/~g of pcD-SR-oe/hlL- 
10 plasmid containing the open reading frame for the human Ibl0 
DNA (15) (obtained originally from DNAX, Inc., Palo Alto, CA) 
and 100 nmol of cationic liposomes.  This plasmid  uses an SV40 
early promoter and the R-U5' sequence of the long terminal repeat 
of human T cell leukemia virus 1 as an enhancer element. The SV40- 
R-U5' promoter-enhancer sequence is shown to yield efficient ex- 
pressions in a variety of cell lines (15). Our previous studies demon- 
strated that maximal expression ofgene transfer by liposomes using 
similar expression vectors occurs after 48 h, and continued expres- 
sion is observed in varying tissues for periods up to 14 d (I2). As 
a  control,  mice  were injected with  200  /~g  of plasmid  DNA 
(pCMV5) without the insert, and mixed with cationic liposomes 
(100 nmol) or administered liposomes alone. 
After 48 h, the mice were killed by cervical dislocation, and the 
organs  were rapidly removed and  frozen immediately in liquid 
nitrogen. Total cellular RNA was isolated  from frozen organs by 
homogenization  in  10  wt/vol  of a  commercial acidic  phenol, 
guanidinium isothiocyanate solution (gNAazol B|  Tel-Test, Inc., 
Friendswood, TX), and precipitation with isopropanol. Reverse 
transcription (RT)-PCR was performed on total cellular RNA ac- 
cording to the manufacturer's specifications (RNA-PCR; Perkin- 
Elmer  Cetus  Instruments,  Norwalk,  CT)  with  the  following 
modifications: 1/~g of total cellular RNA was reverse transcribed 
with 50 U  Moloney murine leukemia virus reverse transcriptase 
for 10 min  at room temperature and subsequently at 42~  for 
30 min using oligo-d(T) as a template.  The PCR was performed 
with 0.5 vol of the reverse transcriptase mixture,  1.25 U  of Taq 
DNA polymerase, and 2.5 #1 of 20 #M sense and antisense primers 
(sequences described below). The reaction was run at 30 cycles com- 
prised of 94~  for 45 s, 60~  for 45 s, and 72~  for 2 rain. After 
completion of the 30 cycles, an additional primer extension period 
of 7 min at 72~  was performed. The DNA products were then 
run on a 1% agarose  gel with  I/~g/ml ethidium bromide. 
The primer sequences used for Ibl0 were 5'-CTG AAG ACT 
TTC TTT CAA ACA AAG-Y and 3'-CTG CTC CAC TGC CTT 
GCT CTT ATT-5', and were obtained from Stratagene, Inc.  (La 
Jolla, CA). The region amplified corresponds to a 208-bp expected 
product size. Sense primer mismatch with murine Ibl0 cDNA was 
7 of 20 bp,  and antisense  primer mismatch was 4 of 20 bp. 
The primer sequences used for p55 were 5'-CTG GTG CTC 
CTG GAG CTG TT-3' and 3'-TC TGT GAC GGA GTC GAC 
GAG-5' The region amplified  corresponds to a 271-bp expected 
product size. 
Immune-reactive human  p55  and  IL-IO were determined by 
ELISA on cell-flee factions from homogenized organs. Very briefly, 
organs were homogenized in 5 wt/vol of PBS containing a pro- 
tease inhibitor cocktail (16). After centrifugation at 19,000 g for 
30 rain at 4~  the supernatant was assayed for human p55 and 
human IL-10 immunoactivity using ELISAs that have been previ- 
ously shown not to cross-react  with the murine p55 and Ibl0, 
respectively. 
Endotoxemic Shock.  Three studies  were performed.  Healthy 
C57BL/6j mice were injected i.p.  with 200/zg of a pCMV/p55 
or pcD-SR-odhlL-10  plasmid mixed with 100 nmol of cationic lipo- 
somes  containing equimolar ratios of DDAB:DOPE  in a  total 
volume of 200 #1. As a control, mice were injected with 200 #g 
ofplasmid DNA (pCMV5) without an insert mixed with cationic 
liposomes (100 nmol) or administered lipososomes  alone. 
After 48 h, animals were challenged with 250 ng of Escherichia 
coli 0127:B8 LPS and 18 mg D-galactosamine (D-gaiN) administered 
i.p. At 90 min, mice were bled from the tail, and serum TNF bio- 
activity assayed using the WEHI 164 clone 13 cytotoxicity assay 
(4).  Survival  over the next 72 h was  evaluated. 
Direct Lung Injury.  Under pentobarbital anesthesia (35 mg/kg 
body wt), a midline incision was made on the ventral aspect of 
the neck and the trachea identified after blunt dissection.  The tra- 
chea was reflected forward by inserting a small plastic loop behind 
the trachea. Using a 30-gauge needle, 50 #g of pCMV/p55 or pcD- 
SR-c~/hlL-10 mixed with 25 nmol of DDAB:DOPE liposomes (in 
25 #1) was instilled directly into the trachea.  The skin wound was 
closed with a surgical  clip,  and the animals  were allowed  to re- 
cover.  2  d  later,  the  skin  wound  was  reopened under  general 
anesthesia,  and 10/~g'ofE. coli 0127:B8 LPS in 25/~1 of saline was 
reinstilled  into the lung. 5 h later, the animals were killed and the 
lungs were removed and frozen in liquid nitrogen. TNF-ot im- 
munoactivity on the cell-free lung homogenates was determined 
by ELISA,  and neutrophil infiltration was  documented by my- 
eloperoxidase (MPO) activity (17). The murine TNF-a ELISA in- 
corporates an mAb (MP6-XT3; PharMingen, San Diego, CA) (1 
#g/ml) as the capture protein, a polyclonal rabbit antisera (A-0123; 
Cornell University Medical College, New York),  as the primary 
antibody (1:100), and a commercially available horseradish  peroxi- 
dase-conjugated,  goat  anti-rabbit  antisera  (Promega  Corp., 
Madison,  WI) (1:8,000) to visualize the protein. Recombinant mu- 
rine TNF-ot (Upstate Biotechnology, Inc., Lake Placid, NY) serves 
as the standard.  Sensitivity of the assay is 34 pg/ml. 
Data Analysis.  Differences in  survival  between  control and 
plasmid-infused  animals  were determined by Fisher's  exact  test. 
Differences in cytokine and MPO concentration were determined 
by ANOVA with Newman-Keuls post hoc multiple range test. 
Statistical significance was designated at the 95% confidence interval. 
Results and Discussion 
48 h after plasmid/liposome injections, healthy C57BL/6j 
mice were killed, and human p55 or IL-10 mRNA expres- 
sion in organs of the reticuloendothelial system was evalu- 
ated by RT-PCR using primers specific for the human pro- 
teins. As shown in Fig. 1, both human p55 and IL-10 mRNA 
expression was  observed in  spleen,  liver, kidney,  and  lung 
of animals administered liposomes containing the appropriate 
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and p55 mRNA. Mice  received  i.p. injections  of 100 #g DNA in 50 nmol 
DDAB:DOPE cationic  liposomes,  or cationic  liposomes  alone, as described 
in the manuscript. 48 h later, animals  were killed and organs were re- 
moved. The presence of human Ibl0 or p55 mRNA was confirmed  by 
RT-PCR. 
DNA. Immune-reactive IL-IO and p55 could also be detected 
in these organ homogenates. In the case of human p55, con- 
centrations ranged from 0.4 to 7.1 ng/g of tissue, with highest 
levels in the spleen and lowest in the lung. For IL-10, con- 
centrations ranged between 350 and 800 pg/g tissue.  How- 
ever, human IL-10 or p55 was not detected in the blood of 
these mice, thus confirming that gene transfer resulted only 
in the local tissue production of these mediators, and quanti- 
ties produced were not sufficient  to be detected in the sys- 
temic circulation. 
The appearance  of both human IL-10 and p55 mRNA in 
lungs from such animals was somewhat unexpected given 
the i.p.  site  of injection. However,  transport of liposomes 
out of the peritoneal cavity via the lymphatics or the circula- 
tion could explain the gene transfer to the lungs. 
To determine the effectiveness  of the antagonists in in- 
hibiting inflammatory responses,  mice transfected with ei- 
ther human IL-IO  or p55  were challenged 48  h  later with 
250 ng LPS and 18 mg D-galN. Lethality  in this LPS-D-galN 
model is dependent on an exaggerated TNF-o~ response, since 
treatment of mice with TNF receptor immunoadhesins (18) 
or the use of TNF receptor (p55)-deficient mice (19) results 
in reduced mortality. Our results from three separate experi- 
ments demonstrated that gene transfer with IL-10 or p55 
improves survival (Table 1). In addition, IL-10 gene transfer 
significantly reduced the plasma TNF-o~ response to LPS-D- 
gaiN.  In the first  experiment, mice were transfected with 
the pCMV5 expression  plasmid without the p55 DNA in- 
sert, whereas, in the remaining two experiments, mice re- 
ceived only liposomes. In either case, survival was not affected 
by administration of either liposomes or liposomes and the 
expression plasmid alone. Thus, local ddivery of these TNF-o~ 
inhibitors to organs of the reticuloendothelial system amelio- 
rated the exaggerated TNF responses and improved survival. 
In additional experiments, mice received the intratracheal 
instillation of liposomes/plasmids containing the DNA for 
IL-10 or p55.  After 48  h,  the trachea was reexposed,  and 
Table  1.  Survival and Peak TNF-~ Concentrations in 
LPS-n-galN  Mice Pretreated with Liposomes Containing 
pCMV/p55 or pcD-SR-oJIL-10 
Experiment  pcD-SK-c~/  Irrelevant 
number  pCMV/p55  hlL-10  DNA/liposomes 
Survived~total  Survived~total  Survived~total 
1  4/6  6/6  1/6 
2  3/6  4/6  0/6 
3  3/6  6/6  1/6 
Totals  10/18#  16/18#  2/18 
TNF-cr 
pg/ml  2,080  _+  810  190  _+  60s  2,690  +_  660 
Mice received the i.p. administration  of 100 #g of plasmid DNA con- 
taining either the pCMV/p55, pcD-SK-oUIL-10, or only  the pCMV5 
plasmid and/or 100 nmol of DDAB:DOPE liposomes. In all three ex- 
periments, survival  was improved  and serum  TNF-c~  concentrations  were 
significantly  reduced  by gene transfer  with IL-10. p55 gene transfer also 
improved outcome  but did not significantly  affect serum TNF-ol con- 
centrations, as measured by WEHI bioassay. 
* In experiment  number 1, control  mice  were pretreated with liposomes 
containing equivalent quantities of pCMV plasmid without the insert. 
In subsequent experiments, only  liposomes were administered. 
*  p <0.01 versus control by Fisher's exact test. 
S  p <0.05 versus control  by ANOVA and Newman-Keuls  multiple  range 
test. 
10 #g of E. coli 0127:B8 LPS in 25 #1 in normal saline was 
instilled. 5 h  after the endotoxin challenge, the mice were 
killed, and lungs were removed for TNF-c~ content and neu- 
trophil infiltration, as measured by myeloperoxidase levels (20). 
Gene transfer with IL-10, but not with p55,  significantly 
reduced the TNF-c~ content of the lung homogenates (Table 
2). Similarly, the degree of neutrophil infiltration  was reduced 
by 55% in IL-10-treated animals but was not reduced in p55- 
treated animals. 
In retrospect, it is not surprising that gene transfer with 
p55 was less effective than IL-10 after i.p.  and intratracheal 
LPS challenge,  given the magnitude of the TNF-ot response. 
We have previously shown in primates that soluble p55 must 
be in a 100-500 molar excess to fully neutralize TNF-ol (4). 
In the present studies,  the quantities of soluble human p55 
recovered from the lungs were only 1-10 times higher than 
the concentrations of TNF-o~, suggesting that the quantities 
of p55 achieved were inadequate to completely inhibit TNF- 
o~-mediated responses.  In addition, the failure of p55 treat- 
ment  to neutralize TNF-c~  activity in either study is not 
surprising, given the nature and stability of the p55-TNF-c~ 
complexes. For example, we showed that treatment orE. coli 
shock in baboons with recombinant p55 attenuated the inflam- 
matory response but only delayed the appearance  of plasma 
TNF-c~ bioactivity (4). Similarly, Mohler et al. observed in- 
creased quantities of TNF activity after an LPS challenge in 
mice administered recombinant p75  TNF receptor (21). 
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pCMV/p55*  pcD-SR-oUhlL-10  Liposomes  Healthy,  control 
TNF-c~, pg/g 
wet wt  500  _+  43  146  _+  58~  382  _+  66  <100 
MPO,  U/g 
wet wt  53.2  _+  1.3  26.4  _+  5.0s  58.7  _+  6.2  1.7  _+  1.7 
Treatment of mice with pcD-SR-ot/hlL-10,  but not pCMV/p55  DNA, attenuates the TNF-ct response and the neutrophil infiltration in the lung, 
as measured by myeloperoxidase activity. 
* The n for each group was 10 animals. 
*/, <0.05  versus liposomes. 
S/~ <0.01  versus liposomes, by ANOVA and Newman-Keuls multiple range test. 
In contrast  to  transfection with  the modified p55,  the 
increased effectiveness of IL-10 gene transfer highlights a ther- 
apeutic advantage associated with cytokines that directly in- 
hibit proinflammatory cytokine production rather than com- 
peting for ligand binding. The concentrations of human IL-10 
achieved in organs of the mice approximate the quantities 
required to down-regulate macrophage activation in vitro (22), 
whereas the levels of p55  are almost three logs lower than 
quantities presumed to neutralize fully the levels of TNF-ot 
achieved  (4). 
Our results underscore several advantages for the use of 
gene transfer as a treatment option for septic shock or other 
acute inflammatory episodes. First, the specificity of targeting 
inhibitors to specific organs is greatly increased. Debs and 
colleagues have shown that aerosol delivery of plasmid DNA 
to rats results in transgene expression occurring only in the 
lung (23), an observation we observed with intratraeheal in- 
stillation. Second, the gene transfer schema permits a con- 
tinued expression of these inhibitors for several days, allowing 
for prolonged delivery of a short-lived antagonist. However, 
since the gene transfer is ultimately transient and the plasmid 
DNA remains episomal, expression efficiencies decline after 
48 h (12). Therefore, the risk of a stable transfection and in- 
corporation of a gene for a potentially immunosuppressive 
agent under a constitutive promoter is remote. Finally, local 
cytokine inhibitors can be directed away from organs where 
the putative beneficial effects of proinflammatory cytokines 
are occurring. 
It should be noted that, in the studies conducted here, the 
gene transfer was delivered 48 h before the inflammatory in- 
sult. The animals were exposed to increased levels of IL-IO 
and p55  for an extended period before the endotoxin chal- 
lenge. It is unlikely that such therapeutic approaches would 
be as advantageous if they were given after the initial inflam- 
matory insult, as is currently being proposed for clinical trials 
with TNF-oe antibodies and immunoadhesins (7, 24). In fact, 
therapeutic efficacy with TNF-c~ inhibitors and IL-1 receptor 
antagonist in patients with sepsis syndrome have produced 
variable results when given several hours after the onset of 
symptomology (7, 24). However, the current study confirms 
that gene transfer is a viable and potentially useful approach 
to targeting individual organs for anticytokine therapies. 
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